[Inflammatory bowel disease: current progress and future aspect].
Ogata
Haruhiko
H
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine.
Hibi
Toshifumi
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D003424:Crohn Disease / Q000235:genetics / Q000503:physiopathology; D016572:Cyclosporine / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D007167:Immunotherapy; D015212:Inflammatory Bowel Diseases / Q000235:genetics / Q000503:physiopathology / Q000628:therapy; D000069285:Infliximab; D007937:Leukapheresis; D017354:Point Mutation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000911:Antibodies, Monoclonal; D016572:Cyclosporine; D000069285:Infliximab